Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York.
Radiat Res. 2024 Nov 1;202(5):745-751. doi: 10.1667/RADE-24-00168.1.
Canine appendicular osteosarcoma (OSCA) is a highly aggressive cancer, constituting 85% of all bone tumors in dogs, predominantly affecting larger breeds and exhibiting a high metastatic rate. This disease also shares many genomic similarities with human osteosarcomas, making it an ideal comparative model for treatment discovery. In this study, we characterized the radiobiological properties of several OSCA cell lines when subjected to spatially fractionated radiation therapy (SFRT) and chemotherapy. Specifically, we focused on lower (peak) doses from SFRT ranging from 1 to 10 Gy. These canine OSCA cell lines serve as useful models for osteosarcoma research that can be utilized to find translational treatments for both canine and human patients. This study reaffirms established clinical wisdom regarding the notoriously radioresistant profile of osteosarcomas but additionally offers compelling evidence supporting SFRT as a promising treatment option that could be used in conjunction with other cytotoxic agents.
犬附肢骨肉瘤（OSCA）是一种高度侵袭性的癌症，占犬类所有骨肿瘤的 85%，主要影响大型犬种，具有较高的转移率。这种疾病与人类骨肉瘤在基因组上有许多相似之处，使其成为治疗发现的理想比较模型。在这项研究中，我们研究了几种 OSCA 细胞系在接受空间分割放射治疗（SFRT）和化疗时的放射生物学特性。具体来说，我们专注于 SFRT 的较低（峰值）剂量范围为 1 至 10 Gy。这些犬骨肉瘤细胞系可作为骨肉瘤研究的有用模型，可用于寻找犬类和人类患者的转化治疗方法。本研究再次证实了骨肉瘤具有众所周知的放射抗性特征的临床经验，但也提供了令人信服的证据，支持 SFRT 是一种有前途的治疗选择，可与其他细胞毒性药物联合使用。
